Company: SACH
Filing Date: 2025-11-14
Form Type: 424B2
Source: 0001628280-25-052333
Chunk: 57

Company: Sachem Capital Corp.
Filing Date: 2025-11-14
Form: 424B2
Chunk 57
---
 more information on this topic. No Securities may be sold without delivery of a prospectus supplement describing the method and terms of the offering of the Securities.

Our common shares are listed on the NYSE American under the symbol “SACH.” On May 15, 2025, the closing sale price of the common shares on NYSE American was $0.94 per share. In addition, we have (i) five series of five-year unsecured unsubordinated notes listed on the NYSE American under the symbols “SCCC”, “SCCD”, “SCCE”, “SCCF”, and “SCCG,” referred to,collectively, in this base prospectus as the “Notes,” and (ii) a 7.75% Series A Cumulative Redeemable Preferred Stock, $0.001 par value per share, listed on the NYSE American under the symbol “SACHPRA,” referred to in this base prospectus as the Series A Preferred Stock.” None of the other Securities are currently listed on any exchange or quoted on any other trading venue or system.

The aggregate market value of our outstanding common shares held by non-affiliates was $52,224,345 based on 45,020,987 outstanding common shares held by non-affiliates on May 15, 2025, and based on the highest reported closing sale price of our common shares of $1.16 per share on April 1, 2025. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell Securities pursuant to this base prospectus and any accompanying prospectus supplement with a value of more than one-third of the aggregate market value of our common shares held by non-affiliates in any 12-month period, so long as the aggregate market value of our common shares held by non-affiliates is less than $75,000,000. In the event that subsequent to the date of this base prospectus, the aggregate market value of our outstanding common shares held by non-affiliates equals or exceeds $75,000,000, then the one-third limitation on sales will not apply to additional sales made pursuant to this prospectus. During the prior 12 calendar months prior to, and including, the date of this prospectus, we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3.

#### See “

#### Risk Factors
” in Item 1A of our Annual Report on Form 10-K, filed March